LATEST NEWS
  •  
    Schreiner MediPharm develops the 10-part label as an extension of its Pharm-Comb series
    Especially in clinical settings, having a multipart label serves a variety of safety and ease-of-use functions for nurses and other healthcare providers (HCPs). It is common in many settings to detach part of the label (which can contain the product name, dosage or other trackable data) and append it to a patient record. The detachable part can also serve as a step in documenting treatment for billing purposes. Overall, the multipart label ensures compliance with the "right drug, right patient ..." mantra of HCPs. To this end, Schreiner MediPharm (Baluvelt, NY) has developed an unusually comprehensive, 10-part
  •  
    Medical cost growth rate has been nearly halved since 2007, but remains above general inflation rates
    The 10th-anniversary report, Medical Cost Trend: Behind the Numbers 2016, from PwC's Health Research Institute projects a 6.5% overall increase, and a net increase (to employer plans and commercial insurers) of 4.5%, for 2016, after factoring in cost-shifting to patients and other changes. That growth rate is down from 2015's 6.8% (projected a year ago), and from 11.9% in 2007, the first year of the HRI report. The cost curve has been bent downward, based on HRI's analysis, but it remains above the general rate of inflation
  •  
    Could PBMs be the big loser in how US healthcare is ultimately reshaped?
    The decision today (June 25) by the US Supreme Court to uphold the essentials of the Affordable Care Act--the ability to provide subsidized insurance via state health exchanges--will likely spur the current merger activity among the biggest health insurance companies--what the Wall Street Journal called a "five-way takeover frenzy." Last week, Anthem Health went public with what is now a $47.5-billion hostile takeover bid for Cigna; previously, UnitedHealth had made an offer for Aetna, and both Cigna and Aetna have reportedly made approaches to Humana. WSJ speculates that federal antitrust regulators would allow only one or two
  •  
    Market-data firm estimates overall 2020 global drug sales at $987 billion
    The annual report from Evaluate Pharma, World Preview 2015, Outlook to 2020, compiles a variety of data on research, drug pipelines, current and projected sales and by its count, the No. 1 biopharma company in the world both in 2014 and 2020, will be Novartis, with projected sales of $53.3 billion (the company tracks only drug sales, and not other businesses that biopharma firms might be engaged in). Pfizer, the longtime No. 1 firm until recently, is projected to remain No. 2, even though 2020 sales will be essentially flat from 2014's $44.5 billion. In fact, the top 20 firms collectively will show CAGR of 3%,
  •  
    Annual Beyond Borders report charts a boom that is continuing into 2015
    The curtain opened on the annual BIO meeting this week (Philadelphia, June 13-18) with the Beyond Borders report from EY's (formerly Ernst & Young) Global Life Sciences Center that couldn't be more optimistic about the biotech sector's current prospects. Based on an analysis of a grouping of biotech-based life sciences companies that EY has been tracking for years, the company found that a host of records were set in 2014: -Net income jumps 231% in 2014 to historic high of US$14.9 billion -R&D spending surged 20% as companies in the US and Europe invested in their pipelines
  •  
    Company hopes to ride a boom in stem-cell and related therapies
    Following a successful debut at the International Soc. for Cellular Therapy (ISCT; Las Vegas, May 27-30), BioLife Solutions says that it is 4-6 weeks away from introducing its Biologistex service to the US market and selected international trade lanes. The Bothell, WA firm sells a variety of preservation media (including hypothermic and cryogenic ranges) that enable cells and tissue samples (including materials for therapeutic use, such as stem cells) to be stored and transported. As an extension of these products, it is introducing Biologistex to enable CROs, cell therapy
  •  
    Company jumps on the latest mobile platform with RepWear and MgrWear for pharma sales forces
    The just-introduced Apple Watch is still feeling its way in the marketplace, trying to address the question whether consumers will want to shrink the apps they use on smartphones to a 1.5-inch screen and performing the legendary Dick Tracy act of talking to your wrist. But IMS Health, now rolling out the Mobile Intelligence CRM platform acquired when it bought Cegedim Relationship Management combined with its IMSOne cloud-based, enterprise-level data and analytics platform, is pushing the edge of the envelope with a platform tailored for Apple Watch, called IMS HealthWear 1.0. HealthWear is initially being offered in two versions:
  •  
    Connectivity now extends to medication history information; effect of preventing medication fraud and abuse
    The SureScripts network, which has been at the forefront of establishing e-prescribing among practitioners and pharmacies, has released its 2014 report, highlighting a growth of 19% in e-prescribing volume over 2013. According to the report, 1.2 billion prescriptions (which SureScripts counts as 67% of new--not refill--prescriptions available to be so prescribed) were transacted in 2014. This occurred with the participation 98% of chain pharmacies, 88% of independent pharmacies and 56% of prescribers. SureScripts is also one of the bright spots in the electronic health record (EHR) environment, where non-interoperability among the hundreds of EHR systems is a painful shortcoming; SureScripts says that it processed
Pharmaceutical Commerce
Digital Edition
Current Digital Edition
Read the July/August 2015 Issue now - It's Free!
COLD CHAIN FOCUS
Pharmaceutical Commerce’s annual Cold Chain Sourcebook projects 44% growth over the 2013–2019 span
 
INDUSTRY EVENTS
 
 
 
 
WHAT THEY'RE SAYING
Pharmaceutical Commerce sat down with Gary McWalters of TGaS Advisors. Here's what he had to say.
 
 
FEATURES
While the biopharma industry continues to develop better treatment options, there is a stronger focus on more intensive patient engagement  continued >
 
New IT tools are propelling a more focused approach to product launch  continued >
 
Control of costs and accounting during clinical trials is a well-known challenge to sponsors. Tools are available  continued >
 
Today's patient population is markedly different from that of generations past.  continued >
 
Combining high-quality patient-support services with comprehensive and continually updated analytics results in better outcomes  continued >
 
 
MOST POPULAR STORIES
 
 
SPECIAL FOCUS REPORT
2015 PDMA Sharing Conference
 
A silver anniversary with golden opportunities
 
CLINICAL OPERATIONS
Looking for a 'paradigm shift' in patient recruitment and retention on an international level 
 
 
 
   
  |     |     |     |     |     |  
©2015 Pharmaceutical Commerce. All Rights Reserved.  |  Website managed and designed by Offenberger & White.